Stoke Therapeutics

Technology
Biotechnology
Health Care
Medical
Therapeutics

Stoke is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.

Suggest edits

Type

B2b

Founded

2017

Raised

$130M

Follow us

Companies in the same industry

Cedilla Therapeutics
Gotham Therapeutics
Imara, Inc.
Artax Biopharma
Engrail Therapeutics
MiNA Therapeutics
Federation Bio
Neuroglee Therapeutics
Care Point Software
Mirna Therapeutics, Inc.

Alexa global traffic share

Built with ❤︎ by Datalicious ©2022
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 2

Add info

Latest funding

$90,000,000

Venture capital (Series B) - 2018

RTW Investments

$40,000,000

Venture capital (Series A) - 2018

Apple Tree Partners

Team Size

10+

Employees

I work here

Location

United States

Headquarters

Explore United States

$90,000,000 Venture capital (Series B)